Community-based data show that increasing categories of severity of hypertension according to the 2017 ACC/AHA BP Guidelines are associated with increasing risk of CVD events in middle age.
PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.
A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.
Expert Consensus Decision Pathways are meant to complement guidelines and bridge remaining gaps in clinical guidance, in this case the use of SGLT2 inhibitors and GLP-1RAs to lower CV risk in T2DM.
The deadline for abstract submission for the 87th edition of the European Society of Atherosclerosis congress, held in Maastricht, The Netherlands, on May 26 - 29, 2019, has been postponed to December 11, 2018.
PCSK9: Outcomes and trials in clinical perspective Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.
ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.
AHA 2018 In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).
Patients with HF with LVEF >40% showed greater total epicardial fat content, which was not related to BMI. Epicardial fat volume was associated with the presence of AF and T2DM.
A small cross-sectional study showed an age-associated rise in BP starting in childhood in a more Westernized community, compared to an isolated, non-acculturated community.
In a population derived from 14 TIMI clinical trials, CV events caused the majority of deaths post-NSTE-ACS, with recurrent MI representing the most common cause of death within the first 30 days, and sudden death after the first 30 days.